Multi-Billion Dollar Drone Cleaning Market Addressed via New UAE Office to Sell Drone-as-a-Service for Power Washing, Plus AI Drone & Quantum Computing Solutions in Varied Industries: ZenaTech, Inc
$ZENA Latest Focus on High Value Defense and Bathymetry Survey Sonar Markets with Field Testing Underway
ZenaTech, Inc. (Nasdaq: ZENA) (FSE: 49Q) (BMV: ZENA) is a technology company specializing in AI drone, Drone as a Service (DaaS), enterprise SaaS and Quantum Computing solutions for mission-critical business applications. Since 2017, ZENA has leveraged its software development expertise and grown its drone design and manufacturing capabilities through subsidiary ZenaDrone, to innovate and improve customer inspection, monitoring, safety, security, compliance, and surveying processes.
With enterprise software customers using branded solutions in law enforcement, health, government, and industrial sectors, and drones being implemented in these plus agriculture, defense, and logistics sectors, the ZENA portfolio of solutions helps drive exceptional operational efficiencies, accuracy, and cost savings. ZENA operates through seven global offices in North America, Europe, Taiwan and UAE, and is growing a DaaS business model and global partner network.
ZenaDrone, a wholly owned subsidiary of ZENA, develops and manufactures autonomous business drone solutions that can incorporate machine learning software, AI, predictive modeling, Quantum Computing, and other software and hardware innovations. Created to revolutionize the hemp farming sector, its specialization has grown to multifunctional drone solutions for industrial surveillance, monitoring, inspection, tracking, process automation and defense applications. Currently, the ZENA ZenaDrone 1000 drone is used for crop management applications in agriculture and critical field cargo applications in the defense sector, the IQ Nano indoor drone is used for inventory management and security in the warehouse and logistics sectors, and the IQ Square is an indoor/outdoor drone designed for land survey and inspections use in commercial and defense sectors.
Expanding Drone Exterior Building Power Washing to Dubai, Tapping into Global Drone Cleaning Services Market Growing to USD 13 Billion by 2030
On May 13th ZENA announced expanding its United Arab Emirates (UAE) presence by establishing a new office to sell Drone-as-a-Service (DaaS) offerings based in Dubai. Initially this office will focus on delivering drone-powered cleaning services for building exteriors using the IQ Square drone tethered to a water pipe and electrical cord. ZENA is currently obtaining a permit from the Dubai Civil Aviation Authority to begin power wash testing and operations. Supporting this expansion, ZENA will hire two business development managers and up to four additional drone pilots, with drones supplied from its subsidiary ZenaDrone which has a manufacturing hub in nearby Sharjah. The global drone power washing market falls under a broader drone cleaning services market category that was valued at approximately USD 4.36 billion in 2023 and is projected to reach USD 13.2 billion by 2030, growing at a compound annual growth rate (CAGR) of almost 17% according to market analyst Valuates Reports, fueled by increasing demand for safe, efficient and cost-effective maintenance solutions.
ZenaDrone Tests Proprietary Camera Enabling IQ Nano Drone Swarms for US Defense Applications and Blue UAS Submission
On May 8th ZENA announced that subsidiary ZenaDrone is testing a new proprietary specialized camera that enables more efficient indoor applications such as inventory and security management, when utilizing IQ Nano drone swarms for commercial and US defense applications. The new ZENA camera prototype developed by its Taiwan component manufacturing subsidiary, Spider Vision Sensors, in collaboration with its certified electronics manufacturing partner, Suntek Global, will enable faster and more precise collection of data including multiple bar codes simultaneously scanned by multiple drones in a drone swarm. ZENA plans to apply for Blue UAS (Unmanned Aerial Systems) certification that lists and validates drones for military and government use.
Military and Defense departments use small autonomous indoor drones like the 10X10 inch IQ Nano for various applications such as inventory management, indoor building reconnaissance, search and rescue, training simulations, and explosives detection. The ZENA ZenaDrone is also engaged in a paid trial which includes developing drone swarm applications for inventory management and security applications with a multinational auto parts manufacturer customer. A drone swarm is a coordinated group of autonomous drones that communicate and work together using AI and real-time data sharing, to perform tasks collaboratively without direct human control.
The ZENA ZenaDrone IQ Nano is available in 10x10 and 20x20-inch sizes, designed to perform regular and frequent inspections such as bar code or RFID scanning, facility maintenance inspections, security monitoring, 3D indoor mapping and other applications inside a warehouse, distribution, or plant facility. It is designed for autonomous use featuring integrated sensors, high-quality cameras, data collection and analysis including AI methodologies. Weighing 1.5kg and with a flight time of at least 20 minutes before utilizing the automatic battery recharging station, it is designed for hovering stability and safety with obstacle avoidance capabilities.
Drone as a Service (DaaS) Offerings Expand to Bathymetric Surveys for Underwater Terrain Mapping for Commercial and Government Customers
On May 1st ZENA announced its DaaS offerings have expanded to include bathymetric surveys, a specialized method of mapping underwater terrain using drones equipped with sonar. These surveys are important for critical underwater depth and contour data to support maintenance, dredging, environmental planning, and aquatic development for both commercial and government customers.
The ZENA DaaS bathymetric surveys are now available in South Florida through the recently acquired Wallace Surveying where the team has both golf course and Intracoastal Waterway project relationships and surveying expertise. Utilizing advanced sonar and ZENA drones, high-resolution underwater maps help customers make informed decisions ─ from enhanced water management and lake and channel design strategies, to ensuring long-term sustainability.
According to DataIntelo market research, the global Bathymetry Survey Sonar Market was valued at approximately $1.2 billion in 2023, this market is projected to reach $2.1 billion by 2032, growing at a CAGR of 6.2%. This encompasses sonar systems utilized in bathymetric surveys, including those deployed on drones.
ZENA DaaS business will incorporate the ZenaDrone 1000 and the IQ series of multifunction autonomous drones to provide a variety of service solutions from land surveys to power line inspections or power washing, made accessible and cost effective through an Uber-like business model on a regular subscription or pay-per-use basis. ZENA customers can conveniently access drones for eliminating manual or time-consuming tasks achieving superior results, such as for surveying, inspections, security and law enforcement, or precision farming applications, without having to buy, operate, or maintain the drones themselves.
The ZENA DaaS business model offers customers such as government agencies, real estate developers, construction firms, farmers or energy companies reduced upfront costs as there is no need to purchase expensive drones, as well as convenience, as there is no need to manage maintenance and operation. The ZENA model also offers scalability to use more often or less often based on business needs and enables access to advanced drone technology sensors or attachments without the need for specialized training.
For more information on $ZENA visit: www.zenatech.com
DISCLAIMER: https://corporateads.com/disclaimer/
Disclosure listed on the CorporateAds website
Media Contact
Company Name: ZenaTech, Inc.
Contact Person: CEO Shaun Passley, Ph.D.
Email: Send Email
Phone: (647) 249-1622
Address:777 Hornby Street, Suite 600
City: Vancouver
State: British Columbia V6Z 1S4
Country: Canada
Website: http://www.zenatech.com
Source: CAP, LLC
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
19 minutes ago
- Business Wire
Alnylam Receives European Commission Approval for AMVUTTRA ® (vutrisiran) for the Treatment of ATTR Amyloidosis with Cardiomyopathy
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNA interference (RNAi) therapeutics company, today announced that the European Commission (EC) has granted approval for the treatment of wild-type or hereditary transthyretin amyloidosis in adult patients with cardiomyopathy (ATTR-CM) as an additional indication for its orphan RNAi therapeutic AMVUTTRA ® (vutrisiran). The approval broadens the indication for AMVUTTRA, which now becomes the first and only RNAi therapeutic approved by the EC for the treatment of the cardiomyopathy manifestations of ATTR amyloidosis and the polyneuropathy manifestations of hereditary transthyretin-mediated amyloidosis (hATTR) in adults. Alnylam Receives European Commission Approval for AMVUTTRA® (vutrisiran) for the Treatment of ATTR Amyloidosis with Cardiomyopathy Share 'Estimates show approximately 100,000 people are affected by ATTR amyloidosis across Europe, most with cardiomyopathy, so this approval marks a critical step toward addressing this underserved patient population,' said Pushkal Garg, M.D., Chief Medical Officer at Alnylam. 'AMVUTTRA is supported by a well-established efficacy and safety profile, with over 6,000 patient-years of global experience in the treatment of hATTR with polyneuropathy. By delivering rapid and sustained knockdown of TTR through convenient, quarterly dosing, it offers a clinically differentiated approach with the potential to transform outcomes for patients living with this debilitating and potentially fatal disease. We now look forward to securing access to AMVUTTRA for eligible patients across the EU as quickly as possible.' The EC decision is based on positive results from the pivotal HELIOS-B Phase 3 study – a randomized, double-blind, placebo-controlled, multicenter, global trial that enrolled a diverse group of patients reflective of the contemporary ATTR-CM population, including those receiving substantial concurrent use of available standard-of-care therapies such as tafamidis and SGLT2 inhibitors. AMVUTTRA met all 10 pre-specified primary and secondary endpoints across both the overall and monotherapy populations. These included statistically significant reductions in all-cause mortality and recurrent cardiovascular events, as well as significant improvements in functional capacity (6-minute walk test), health status and quality of life (Kansas City Cardiomyopathy Questionnaire), and heart failure symptoms and severity (NYHA class). In the overall population, AMVUTTRA achieved a 28% reduction in the primary composite of all-cause mortality and recurrent cardiovascular events as compared to placebo. Mortality in this population was significantly reduced by 36% through 42 months in a pre-specified secondary endpoint analysis which included up to 36 months of the double-blind period plus six months of open-label extension. In HELIOS-B, rates of adverse events (AEs), serious AEs, severe AEs and AEs leading to study drug discontinuation were similar between the AMVUTTRA and placebo arms. Adverse drug reactions of AMVUTTRA include injection site reactions and increase in blood alkaline phosphatase and alanine transaminase. Detailed results from the HELIOS-B study were published in The New England Journal of Medicine. 1 'The HELIOS-B findings provide compelling evidence to support the use of vutrisiran as a first-line treatment option for patients with ATTR-CM,' said Marianna Fontana, M.D., Ph.D., HELIOS-B investigator, Professor of Cardiology, University College London, National Amyloidosis Center, Royal Free Hospital, London. 'As a physician, it is a privilege to see the true impact on patients in the clinic. The trial enrolled a broad population reflective of real-world clinical practice, and that's what makes the results so meaningful. This is a milestone for patients, who now have a new treatment option that has the potential to significantly improve outcomes of this disease.' ATTR-CM is caused by the deposition of misfolded TTR fibrils, which drive progressive and irreversible cardiovascular damage and premature death. AMVUTTRA is an RNAi therapeutic that works upstream by delivering sustained knockdown of disease-causing TTR at its source. In the EU, it is administered as a subcutaneous injection once every three months, either by a healthcare professional, or self-administered by patients or their caregivers, offering flexibility in treatment delivery. 'Amyloidosis is a serious and progressive disease that significantly impacts not only patients' physical health, but also their quality of life and independence. I am thrilled by the news of a new therapy for people in the EU living with ATTR-CM who often face delayed diagnosis. Having a new treatment option available marks a welcome development for the amyloidosis community,' said Giovanni d'Alessio, President of the Amyloidosis Alliance. In May 2025, the European Medicines Agency's Committee for Orphan Medicinal Products (COMP) adopted a positive opinion on the maintenance of the EU Orphan Designation for AMVUTTRA in ATTR amyloidosis. AMVUTTRA was approved in March 2025 by the U.S. Food and Drug Administration (FDA) and the Brazilian Health Regulatory Agency (ANVISA) for the treatment of the cardiomyopathy of wild-type or hereditary ATTR amyloidosis in adults. Alnylam continues to pursue additional global submissions to bring vutrisiran to patients worldwide. Indications In the EU, AMVUTTRA ® (vutrisiran) is indicated for the treatment of: hereditary transthyretin amyloidosis in adult patients with stage 1 or stage 2 polyneuropathy (hATTR-PN). wild-type or hereditary transthyretin amyloidosis in adult patients with cardiomyopathy (ATTR-CM). Important Safety Information Reduced Serum Vitamin A Levels and Recommended Supplementation Vutrisiran treatment leads to a decrease in serum vitamin A levels. Supplementation of approximately, but not exceeding, 2500 IU to 3000 IU vitamin A per day is advised for patients taking vutrisiran. Patients should be referred to an ophthalmologist if they develop ocular symptoms suggestive of vitamin A deficiency (e.g., night blindness). Adverse Reactions Commonly reported adverse reactions with vutrisiran were injection site reactions and increase in blood alkaline phosphatase and alanine transaminase. For additional information about vutrisiran, please see the full Summary of Product Characteristics. About AMVUTTRA ® (vutrisiran) AMVUTTRA ® (vutrisiran) is an RNAi therapeutic that delivers rapid knockdown of variant and wild‑type transthyretin (TTR), addressing the underlying cause of transthyretin (ATTR) amyloidosis. Administered quarterly via subcutaneous injection, vutrisiran is approved and marketed in more than 15 countries for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR-PN) in adults. It is also approved in the U.S. and Brazil for the treatment of wild-type or hereditary ATTR amyloidosis in adult patients with cardiomyopathy (ATTR-CM). In the EU, AMVUTTRA is administered once every three months, either by a healthcare professional or through self-administration by patients or their caregivers. About ATTR Transthyretin amyloidosis (ATTR) is an underdiagnosed, rapidly progressive, debilitating and fatal disease caused by misfolded transthyretin (TTR) proteins, which accumulate as amyloid deposits in various parts of the body, including the nerves, heart and gastrointestinal tract. Patients may present with polyneuropathy, cardiomyopathy or both manifestations of disease. There are two different forms of ATTR – hereditary ATTR (hATTR), which is caused by a TTR gene variant and affects approximately 50,000 people worldwide, and wild-type ATTR (wtATTR), which occurs without a TTR gene variant and impacts an estimated 200,000-300,000 people worldwide. 2-5 About RNAi RNAi (RNA interference) is a natural cellular process of gene silencing that represents one of the most promising and rapidly advancing frontiers in biology and drug development today. 6 Its discovery has been heralded as 'a major scientific breakthrough that happens once every decade or so,' and was recognized with the award of the 2006 Nobel Prize for Physiology or Medicine. 7 By harnessing the natural biological process of RNAi occurring in our cells, a new class of medicines known as RNAi therapeutics is now a reality. Small interfering RNA (siRNA), the molecules that mediate RNAi and comprise Alnylam's RNAi therapeutic platform, function upstream of today's medicines by potently silencing messenger RNA (mRNA) – the genetic precursors that encode for disease-causing or disease pathway proteins – thus preventing them from being made. 6 This is a revolutionary approach with the potential to transform the care of patients with genetic and other diseases. About Alnylam Pharmaceuticals Alnylam (Nasdaq: ALNY) has led the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare and prevalent diseases with unmet need. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach yielding transformative medicines. Since its founding in 2002, Alnylam has led the RNAi Revolution and continues to deliver on a bold vision to turn scientific possibility into reality. Alnylam has a deep pipeline of investigational medicines, including multiple product candidates that are in late-stage development. Alnylam is executing on its ' Alnylam P 5 x25 ' strategy to deliver transformative medicines in both rare and common diseases benefiting patients around the world through sustainable innovation and exceptional financial performance, resulting in a leading biotech profile. Alnylam is headquartered in Cambridge, MA. Alnylam Forward-Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. All statements other than historical statements of fact regarding Alnylam's expectations, beliefs, goals, plans or prospects including, without limitation, Alnylam's expectations regarding the safety and efficacy of AMVUTTRA for the treatment of ATTR-CM; the potential for AMVUTTRA to be used as a first-line treatment for ATTR-CM; the potential for AMVUTTRA to address the underserved ATTR-CM patient population and to improve outcomes for ATTR-CM patients; and Alnylam's ability to secure access to AMVUTTRA for eligible patients across the EU and the timing of such access should be considered forward-looking statements. Actual results and future plans may differ materially from those indicated by these forward-looking statements as a result of various important risks, uncertainties and other factors, including, without limitation, risks and uncertainties relating to: Alnylam's ability to successfully execute on its ' Alnylam P 5 x25 ' strategy; Alnylam's ability to successfully demonstrate the efficacy and safety of its product candidates; the pre-clinical and clinical results for Alnylam's product candidates; actions or advice of regulatory agencies and Alnylam's ability to obtain regulatory approval for its product candidates, as well as favorable pricing and reimbursement; successfully launching, marketing and selling Alnylam's approved products globally; and any delays, interruptions or failures in the manufacture and supply of Alnylam's product candidates or its marketed products; as well as those risks more fully discussed in the 'Risk Factors' filed with Alnylam's 2024 Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC), as may be updated from time to time in Alnylam's subsequent Quarterly Reports on Form 10-Q and in its other SEC filings. In addition, any forward-looking statements represent Alnylam's views only as of today and should not be relied upon as representing its views as of any subsequent date. Alnylam explicitly disclaims any obligation, except to the extent required by law, to update any forward-looking statements.
Yahoo
22 minutes ago
- Yahoo
Got $1,000? Super Micro Computer Stock Is a Brilliant Backdoor AI Play
Super Micro Computer's DLC technology offers huge cost savings for companies constructing data centers. Supermicro faces some headwinds due to tariffs. Supermico's stock looks cheap compared to many other AI players. 10 stocks we like better than Super Micro Computer › There are many ways to play the AI investment trend. Hardware companies like Nvidia (NASDAQ: NVDA) are powering the training of AI models, suppliers like Taiwan Semiconductor (NYSE: TSM) are building the chips for Nvidia, and software companies like Palantir (NASDAQ: PLTR) are providing platforms to deploy AI for real-world use. I tend to prefer neutral options in the AI space. That way, I can benefit from the general buildout of AI rather than having one company succeed. While Nvidia is an excellent choice in this realm, so is Super Micro Computer (NASDAQ: SMCI). Super Micro Computer, often called Supermicro, builds server racks and cooling solutions for data centers to house high-powered computing devices like Nvidia's GPUs. Supermicro has seen impressive growth over the past few years, but what's ahead could make investors even more money. Server racks are fairly commoditized, so there isn't much to separate one competitor from another. However, one area where a company can make a name for itself is customizability and cooling technology. Supermicro's racks are highly modular, allowing clients of all sizes to find a server rack that fits their workload size and application. Another advantage of Supermicro's solutions is its direct liquid-cooling (DLC) technology. Traditionally, computing hardware is cooled by moving air across the unit, which isn't the most efficient way to cool these units. Supermicro's DLC technology moves liquid across the surface (contained in tubes), which is a far more efficient way to cool them. Furthermore, because these units don't have to account for airflow, Supermicro's clients can pack more server racks into a given space, which helps decrease building costs. Supermicro estimates that this provides up to 40% energy savings and 80% space savings. Supermicro also has key partnerships in the industry, most notably with Nvidia. Nvidia's most powerful chip, based on Blackwell architecture, can be placed in servers purpose-built to hold those exact GPUs, helping users squeeze out every last bit of performance from these chips. In Supermicro's third quarter of fiscal year 2025 (ended March 31), sales rose 19% year over year to $4.6 billion. While that's solid growth, the company faces some headwinds due to tariffs. Supermicro also faces some headwinds moving into next quarter, with revenue expected to be about $6 billion at the midpoint of guidance, indicating 13% growth. However, one area where Supermicro shines is its valuation, as shares can be scooped up for a dirt-cheap level. Supermicro's stock trades for just 15.2 times fiscal year 2026's earnings, which is far cheaper than most of the AI stocks in the market, which commonly trade in the high-20s to the low-30s range. As Supermicro figures out tariffs and shifts supply chains around, it could see its growth start to reaccelerate, as AI demand is still massive. Nvidia forecast, using third-party data, that data center capital expenditures would reach $400 billion in 2024 but could rise to $1 trillion by 2028. Should this occur, Supermicro will see its business rapidly expand due to the field in which it's playing. That kind of growth could send Supermicro's stock soaring if it can capture the bulk of server infrastructure, making Supermicro a potentially fantastic buy to capitalize on the AI arms race that's still heating up. Before you buy stock in Super Micro Computer, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Super Micro Computer wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $669,517!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $868,615!* Now, it's worth noting Stock Advisor's total average return is 792% — a market-crushing outperformance compared to 173% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 2, 2025 Keithen Drury has positions in Nvidia and Taiwan Semiconductor Manufacturing. The Motley Fool has positions in and recommends Nvidia, Palantir Technologies, and Taiwan Semiconductor Manufacturing. The Motley Fool has a disclosure policy. Got $1,000? Super Micro Computer Stock Is a Brilliant Backdoor AI Play was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
25 minutes ago
- Yahoo
Corporate Layoffs Surge Despite Strong Jobs Data
Corporate America is slashing jobs even as U.S. economic data looks solid: despite April's jobs report beating expectations, ADP data showed private-sector hiring hit a two-year low, and companies are cutting staff to rein in costs amid lingering economic uncertainty and tariff pressures. Automation and AI are major factors: Klarna CEO Sebastian Siemiatkowski admitted its workforce shrank by 40% partly due to AI investments, while Shopify's (NASDAQ:SHOP) CEO Tobias Lutke now tells employees they must prove a task can't be done by AI before requesting more headcount or resources. Big-name layoffs illustrate the trend: Procter & Gamble (NYSE:PG) is trimming 7,000 roles (about 15% of its non-manufacturing staff), Microsoft (NASDAQ:MSFT) is axing 6,000 positions, Citigroup (C) will cut 3,500 jobs in its China IT services arm, and Walmart (NYSE:WMT) plans to let go 1,500 workers across technology, operations, e-commerce and advertising units. Other reductions include CrowdStrike (NASDAQ:CRWD) cutting 500 roles, Disney (NYSE:DIS) scaling back film and TV divisions, and Amazon (NASDAQ:AMZN) trimming 100 jobs in its devices unit. Even as the federal government winds down its Department of Government Efficiency initiative, which once drove thousands of federal job cuts, private-sector layoffs persist, highlighting how firms are choosing automation and AI as key levers to navigate tighter margins. Investors should watch if these tech-driven cuts translate into lower operating costs and improved margins, or if reduced headcount pressures product development and growth. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
